Improving techniques for treating pathological scar deformities of the skin is a serious medical and social problem that still remains topical due to the increased expectations of patients and doctors regarding aesthetic results and a marked effect of pathological skin changes on the psycho-emotional sphere, social status, and social adaptation of patients. Purpose. The study purpose was to develop a new technique for treating pathological scar deformities of the skin by means of one-step application of a drug in combination with a physical factor. Material and methods. The proposed treatment was used in 50 patients with skin scar deformities of a different location, severity, and a phase of scar tissue formation. The proposed treatment was as follows. Patient’s scar tissue was pretreated with a conjugated preparation of hyaluronidase (hyaluronidase activity of 3000 IU), followed by exposure of the scar tissue to a running pulsed magnetic field through four channels. The magnetic induction amplitude on the coil working surface of a device coil group was 20±6 mT; the magnetic field pulse duration was 1.5—2.5 ms; the magnetic field pulse repetition frequency in each coil was 6 Hz. The mean course of treatment using the proposed technique was 10 procedures for hypertrophic scars and 15 procedures for keloid scars. Results. Patients with scar deformities of the skin had a marked positive improvement of the main symptoms of the disease: by the end of the treatment course, 94% of patients had a clinical remission or significant improvement (resolution of pathological skin lesions by 75% and more), and 6% of patients had an improvement. The treatment improved the subjective state of patients and the clinical course of the disease, reduced the drug dose, and prolonged the remission period by improving the functional state of the skin. Conclusions. The proposed treatment option has a local effect on the scarring process, provides a pronounced anti-inflammatory, fibrinolytic, and immunocorrective effect, and improves the microcirculation, efficacy of treatment, and patient’s quality of life. The described treatment option was patented in 2016 (a patent of the Russian Federation №2599868).